FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916061279> ?p ?o ?g. }

• W2916061279 abstract "Numerous multicenter clinical trials have demonstrated the efficacy of antivascular endothelium growth factor (VEGF) therapy for multiple retinal and choroidal vascular diseases. Although generally well tolerated, certain complications can occur, while rare, ocular vascular events have been reported following anti-VEGF injections in several prior studies (Papadopoulou et al. 2009; Bonnin et al. 2010; von Hanno et al. 2010; Mansour et al. 2010, 2012). We aim to determine the incidence of retinal artery occlusion (RAO) and to assess associated clinical features in patients undergoing intravitreal anti-VEGF injections. All patients receiving intravitreal anti-VEGF injections from 1 January 2016 to 31 December 2017 who also developed a RAO from a large tertiary care retina practice were identified in this retrospective study. A total of 16 686 unique patients received 125 108 anti-VEGF injections during the study period. Twelve patients developed a RAO (eight cases of central RAO and four cases of branch RAO) within 90 days of injection, resulting in an incidence of 1/1389 (0.072%). There were six males and six females with an average age of 81.9 ± 10.4 years (range: 58–94 years). A prior history of systemic hypertension was documented in 91.7% of patients (11 out of 12). Four patients underwent injections for AMD, one for DME, three for central retinal vein occlusion (RVO) and four for branch RVO. Prior to RAO occurrence, bevacizumab was injected in one case, ranibizumab in seven cases and aflibercept in four cases. The average period from the closest injection to RAO diagnosis was 37.0 ± 19.3 days (range: 14–70 days). The mean logarithm of the minimal angle of resolution visual acuity decreased from 0.43 ± 0.37 (20/54 Snellen equivalent) at the visit preceding diagnosis of RAO to 1.63 ± 1.10 (20/853 Snellen equivalent) after the occurrence of RAO. Table 1 shows no statistically significant difference of RAO incidence based on gender, age or laterality. The incidence of RAO varied by underlying ocular disease. Retinal artery occlusion (RAO) occurred in four out of 8212 (0.05%) patients with AMD, one out of 3502 (0.03%) patients with DME, seven out of 2811 (0.25%) patients with RVO and 0 out of 2161 patients receiving injections for other conditions. There was a significant difference in the rate of RAO only between AMD and RVO patients (p = 0.01). Retinal artery occlusion (RAO) occurred in one of 18 125 bevacizumab injections (0.006%), seven of 54 019 ranibizumab injections (0.013%) and four in 52 964 aflibercept injections (0.008%). No significant difference was found between these three groups (p = 0.55). There was a significant difference in RAO incidence between patients with hypertension and those without (p < 0.001). However, no difference was detected between patients with diabetes and those without diabetes (p = 0.41). Of the 10 of 13 088 patients undergoing unilateral injections, no RAO was detected in the fellow eye (p = 0.001). Due to its retrospective nature, there is an absence of controls in the current study. Nevertheless, from this large database, RAO was detected in approximately 1 in 1389 patients following intravitreal anti-VEGF injection. Anti-VEGF medications have been associated with vasoconstriction, decreased blood flow velocity (Sacu et al. 2011), as well as an increase in activated platelets, all of which can increase the risk of developing a RAO. However, it is unknown whether RAO was related to the intravitreal injection procedure, injected drug or comorbidities of these patients. Larger population-based studies may help confirm these findings and elucidate other underlying risk factors." @default.
• W2916061279 created "2019-03-02" @default.
• W2916061279 creator A5022551584 @default.
• W2916061279 creator A5027369181 @default.
• W2916061279 creator A5028858400 @default.
• W2916061279 creator A5031536941 @default.
• W2916061279 creator A5042846805 @default.
• W2916061279 creator A5073945118 @default.
• W2916061279 date "2019-02-27" @default.
• W2916061279 modified "2023-10-16" @default.
• W2916061279 title "Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections" @default.
• W2916061279 cites W1983275936 @default.
• W2916061279 cites W2016212397 @default.
• W2916061279 cites W2042114071 @default.
• W2916061279 cites W2056398240 @default.
• W2916061279 cites W2072434933 @default.
• W2916061279 cites W2106557635 @default.
• W2916061279 doi "https://doi.org/10.1111/aos.14058" @default.
• W2916061279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30810272" @default.
• W2916061279 hasPublicationYear "2019" @default.
• W2916061279 type Work @default.
• W2916061279 sameAs 2916061279 @default.
• W2916061279 citedByCount "10" @default.
• W2916061279 countsByYear W29160612792019 @default.
• W2916061279 countsByYear W29160612792020 @default.
• W2916061279 countsByYear W29160612792021 @default.
• W2916061279 countsByYear W29160612792022 @default.
• W2916061279 crossrefType "journal-article" @default.
• W2916061279 hasAuthorship W2916061279A5022551584 @default.
• W2916061279 hasAuthorship W2916061279A5027369181 @default.
• W2916061279 hasAuthorship W2916061279A5028858400 @default.
• W2916061279 hasAuthorship W2916061279A5031536941 @default.
• W2916061279 hasAuthorship W2916061279A5042846805 @default.
• W2916061279 hasAuthorship W2916061279A5073945118 @default.
• W2916061279 hasBestOaLocation W29160612791 @default.
• W2916061279 hasConcept C118487528 @default.
• W2916061279 hasConcept C120665830 @default.
• W2916061279 hasConcept C121332964 @default.
• W2916061279 hasConcept C141071460 @default.
• W2916061279 hasConcept C2776268601 @default.
• W2916061279 hasConcept C2776694085 @default.
• W2916061279 hasConcept C2777802072 @default.
• W2916061279 hasConcept C2778749236 @default.
• W2916061279 hasConcept C2778844676 @default.
• W2916061279 hasConcept C2780261187 @default.
• W2916061279 hasConcept C2780347916 @default.
• W2916061279 hasConcept C2780827179 @default.
• W2916061279 hasConcept C2781100027 @default.
• W2916061279 hasConcept C2909556870 @default.
• W2916061279 hasConcept C61511704 @default.
• W2916061279 hasConcept C71924100 @default.
• W2916061279 hasConceptScore W2916061279C118487528 @default.
• W2916061279 hasConceptScore W2916061279C120665830 @default.
• W2916061279 hasConceptScore W2916061279C121332964 @default.
• W2916061279 hasConceptScore W2916061279C141071460 @default.
• W2916061279 hasConceptScore W2916061279C2776268601 @default.
• W2916061279 hasConceptScore W2916061279C2776694085 @default.
• W2916061279 hasConceptScore W2916061279C2777802072 @default.
• W2916061279 hasConceptScore W2916061279C2778749236 @default.
• W2916061279 hasConceptScore W2916061279C2778844676 @default.
• W2916061279 hasConceptScore W2916061279C2780261187 @default.
• W2916061279 hasConceptScore W2916061279C2780347916 @default.
• W2916061279 hasConceptScore W2916061279C2780827179 @default.
• W2916061279 hasConceptScore W2916061279C2781100027 @default.
• W2916061279 hasConceptScore W2916061279C2909556870 @default.
• W2916061279 hasConceptScore W2916061279C61511704 @default.
• W2916061279 hasConceptScore W2916061279C71924100 @default.
• W2916061279 hasIssue "6" @default.
• W2916061279 hasLocation W29160612791 @default.
• W2916061279 hasLocation W29160612792 @default.
• W2916061279 hasOpenAccess W2916061279 @default.
• W2916061279 hasPrimaryLocation W29160612791 @default.
• W2916061279 hasRelatedWork W2267923302 @default.
• W2916061279 hasRelatedWork W2578851731 @default.
• W2916061279 hasRelatedWork W2588621177 @default.
• W2916061279 hasRelatedWork W2885315742 @default.
• W2916061279 hasRelatedWork W3158593454 @default.
• W2916061279 hasRelatedWork W4205243730 @default.
• W2916061279 hasRelatedWork W4206282206 @default.
• W2916061279 hasRelatedWork W4281812343 @default.
• W2916061279 hasRelatedWork W4301352144 @default.
• W2916061279 hasRelatedWork W775501514 @default.
• W2916061279 hasVolume "97" @default.
• W2916061279 isParatext "false" @default.
• W2916061279 isRetracted "false" @default.
• W2916061279 magId "2916061279" @default.
• W2916061279 workType "article" @default.